Yazar "Derman, O" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Distinguishing features of Salmonella and viral hepatitis(Lippincott Williams & Wilkins, 2000) Gürkan, F; Derman, O; Yaramis, A; Ece, A[Abstract Not Available]Öğe The novel genetic disorder microhydranencephaly maps to chromosome 16p13.3-12.1(Univ Chicago Press, 2000) Kavaslar, GN; Önengüt, S; Derman, O; Kaya, A; Tolun, AWe studied a large consanguineous Anatolian family with children who exhibited hydranencephaly associated with microcephaly. The children were severely affected. This novel genetic disorder is autosomal recessive. We used autozygosity mapping to identify a locus at chromosome 16p13.3-12.1; it has a LOD score of 4.11. The gene locus is within a maximal 11-cM interval between markers D16S497 and D16S672 and within a minimal critical region of 8 cM between markers D16S748 and D16S490.Öğe A portable device based on the interrupter technique for measuring airway resistance in preschool children(Hogrefe & Huber Publishers, 2004) Derman, O; Yaramis, A; Kirbas, GThe interrupter technique for measuring airway resistance is a noninvasive method reported to require minimal subject cooperation. Therefore it has a good potential for use in young children who are not able to cooperate with conventional lung function tests. The interrupter method is based on transient interruption of airflow at the mouth for a brief period during which alveolar pressure equilibrates with mouth pressure. In order to investigate the compliance rate with the interrupter technique in preschool children and to look for associated baseline measures of RINT we performed a study in 214 children of ages from 3 months to 5 years. There was a significant inverse correlation between baserint and age (r = -0.672, p < 0.001), and standing height (r = -0.692, p < 0.001) in children with recurrent wheezing. However, this was not seen in healthy children. We concluded that the portable interrupter device is very useful in preschool children. The measurements showed that the a-e and standing height are inversely proportional to the baseline RINT values measured. We reported that these differences would be more apparent in children with a history of recurrent wheezing.Öğe A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia(Amer Acad Pediatrics, 2001) Bilgin, K; Yaramis, A; Haspolat, K; Tas, A; Günbey, S; Derman, OObjectives. To determine whether adjunctive therapy with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) could reverse sepsis-associated neonatal neutropenia and improve neonatal survival and to assess its safety compared with conventional therapy in a control group. Study Design. This prospective, randomized, controlled trial was performed in 60 infants with neutropenia and clinical signs of sepsis. A subcutaneous injection of rhGM-CSF (5 mug/kg/day) was administered to 30 of the patients for 7 consecutive days. Hematologic parameters (absolute neutrophil, eosinophil, monocyte, lymphocyte counts, and platelet number) and outcome were compared with 30 conventionally treated (control) patients. Results. Twenty-five patients from the GM-CSF-treated group and 24 from the conventionally treated group had early-onset sepsis (less than or equal to3 days' postnatal age), and the other 11 patients had late-onset sepsis (>3 days' postnatal age). There was no difference between groups in terms of birth weight; gestational age; gender; maturity; maternal age; and incidence of prolonged rupture of membranes, maternal hypertension, or severity of sepsis. All neonates tolerated GM-CSF well with no adverse reactions. The absolute neutrophil count on day 7 was significantly increased in the GM-CSF-treated group compared with the conventionally treated group: 8088 +/- 2822/mm(3) versus 2757 +/- 823/mm(3). The mean platelet count was significantly higher on days 14 in the GM-CSF-treated group compared with conventionally treated group: 266 867 +/- 55 102/mm(3) versus 229 200 +/- 52 317/mm(3). Hematologic parameters were otherwise similar between groups before treatment and on day 28. Twenty-seven neonates in the rh-GMCSF group and 21 in the control group survived to hospital discharge. The mortality rate in the rhGM-CSF group (10%) was significantly lower than in the conventionally treated group (30%). Conclusion. Treatment with rhGM-CSF is associated with an increase in absolute neutrophil, eosinophil, monocyte, lymphocyte, and platelet counts and decreased mortality in critically ill septic neutropenic neonates. These results suggest that rhGM-CSF may be effective in the treatment of neonatal sepsis with neutropenia, and further randomized trials are needed to confirm its beneficial effects.Öğe Severe microangiopathic hemolytic anemia and thrombocytopenia in a child with Brucella infection(Springer-Verlag, 2001) Yaramis, A; Kervancioglu, M; Yildirim, I; Soker, M; Derman, O; Tas, MAWe present a case of severe microangiopathic hemolytic anemia and thrombocytopenia with epistaxis, gross hematuria, hemoglobinuria. and skin purpura in a child with Brucella septicemia proven by culture. The patient showed the features of this illness: leukopenia, severe hemolytic anemia, thrombocytopenia, fragmentation of erythrocytes in the peripheral blood smear, increased erythropoiesis, megakaryopoiesis, and granulomata cell invasion in the bone marrow. The patient was treated with rifampin and doxycycline. Platelets and leukocyte numbers rose to normal values by the 6th day. She was discharged on the 14th day. Follow-up of the patient 1 year later showed normal bone marrow morphology. Differential diagnosis, pathogenesis, and therapy of Brucella infection are discussed.
